

# The **unique needs** of women require different clinical insights

## With Quest women's health testing, you can address her health challenges

Whether your patient's needs are routine or complex, Quest offers the cervical cancer screening and prenatal testing you need to improve care and meet quality measures.



## Cervical cancer co-testing: highly accurate and smart

Our cervical cancer screening co-testing solutions combine carefully evaluated Pap and high-performing mRNA testing for high-risk HPV. Co-testing has been shown to identify more cases of pre-cancer and cancer than either Pap or HPV testing alone.<sup>1,2</sup>

↑ **59.7%**

### Higher detection of high-grade lesions

ThinPrep® Pap test vs conventional Pap testing<sup>3</sup>

↓ **24%–37%**

### Reduction in false positives

Aptima® HPV mRNA testing vs HPV DNA testing<sup>4,5</sup>



**Age-based Smart Codes** make it easy to order both the cervical cancer screening and STI tests your patients need, consistent with ACOG guidelines—spend more time with patients and less time searching for multiple codes.



**Enhanced CytoComplete™ reports** integrate Pap and HPV results for all the information you need at a glance.

Quest cervical cancer screening can help you **provide the best possible care for your patients and achieve key quality measures** by improving adherence to screening requirements.

# Comprehensive testing throughout the reproductive journey

We offer routine to advanced testing as well as professional consultation to support you in delivering the very best reproductive care to medically underserved women.



## Preconception

**QHerit® Expanded Carrier Screen is a pan-ethnic carrier screen panel that tests for 22 hereditary diseases, including:**

- Cystic Fibrosis
- Fragile X
- SMA
- AJ Panel
- Thalassemias

The American College of Obstetricians and Gynecologists (ACOG) recommends all individuals, regardless of race or ethnicity, be offered screening for the same set of conditions.<sup>6</sup>



## Prenatal screening and diagnostic testing

**First trimester (0–13 weeks) testing includes:**

- First Trimester Screen, hCG
- Stepwise Sequential Screen Part 1
- QNatal® Advanced Noninvasive Prenatal Screening
- Chorionic Villus Sampling (CVS)

**Second trimester (14–26 weeks) includes:**

- Stepwise Sequential Screen Part 2
- Quad Screen
- Maternal Serum Alpha-Fetoprotein
- Amniocentesis

Pregnancy tests recommended by ACOG include important laboratory tests performed in all pregnant women throughout their pregnancy. **For details on these tests, please refer to this comprehensive resource.**



The QNatal Advanced test reports fetal sex<sup>†</sup> and the most common chromosomal abnormalities:

- Trisomy 21 (Down Syndrome)
- Trisomy 18 (Edwards Syndrome)
- Trisomy 21 (Patau Syndrome)

It also reports sex chromosome abnormalities and 7 microdeletions.<sup>a</sup>

## Wondering which genetic test to order?

Have questions about results interpretation, patient eligibility, or mutation reclassification? Consult with one of our board-certified medical geneticists or lab-based genetic counselors. All counselors are certified by the American Board of Genetic Counseling.



**1.866.GENE.INFO (1.866.436.3463)**

## Demand the best in women's health testing for your patients

Let us help you get the results you need, when you need them. Ask your Quest representative for details.

<sup>a</sup> Can opt out and the information will not be reported.

### References

1. Blatt AJ, Kennedy R, Luff RD, Austin RM, Rabin DS. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. *Cancer Cytopathol.* 2015;123:282–288. doi: 10.1002/cncy.21544 2. Austin RM, Onisko A, Zhao C. Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV cotesting. *Am J Clin Pathol.* 2018;150(5):385–392. doi: 10.1093/ajcp/aqy114 3. ThinPrep 2000 system [package insert]. MAN-02624-001 Rev.004. Marlborough, MA; Hologic, Inc.; 2017. 4. Monsonego J, Hudgens MG, Zerat L, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. *Int J Cancer.* 2011;29(3):691–701. doi: 10.1002/ijc.25726 5. Cuzick J, Cadman L, Mesher D, et al. Comparing the performance of six human papillomavirus tests in a screening population. *Br J Cancer.* 2013;108(4):908–913. doi: 10.1038/bjc.2013.22 6. The American College of Obstetricians and Gynecologists. Carrier screening for genetic conditions. March 2017. Accessed July 28, 2020. <https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions>.

### QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. ©2020 Quest Diagnostics Incorporated. All rights reserved. SB9556 8/2020

